Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 88.0%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 2,177 shares, a growth of 88.0% from the November 30th total of 1,158 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average daily volume of 82,197 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 82,197 shares, the short-interest ratio is presently 0.0 days. Currently, 0.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BOLT. Zacks Research cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright set a $7.00 price target on shares of Bolt Biotherapeutics and gave the company a “buy” rating in a report on Monday, October 20th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bolt Biotherapeutics presently has an average rating of “Hold” and an average target price of $34.00.

Institutional Trading of Bolt Biotherapeutics

Institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP acquired a new position in Bolt Biotherapeutics during the third quarter valued at approximately $89,000. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics in the third quarter worth $85,000. Finally, Squarepoint Ops LLC grew its position in shares of Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares during the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

Shares of BOLT opened at $5.33 on Monday. The company has a market capitalization of $10.23 million, a PE ratio of -0.24 and a beta of 0.93. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. Bolt Biotherapeutics has a one year low of $4.41 and a one year high of $12.60. The company’s fifty day moving average price is $5.25 and its 200 day moving average price is $5.48.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.07) by $1.35. The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $0.82 million. As a group, analysts expect that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.